Watson Health and Pfizer Inc. today announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer’s research in immuno-oncology, an approach to cancer treatment that uses the body’s immune system to help fight cancer. Pfizer is one of the first organizations worldwide to deploy Watson for Drug Discovery, and the first to customize the cloud-based cognitive tool – tapping into Watson’s machine learning, natural language processing, and other cognitive reasoning technologies to support the identification of new drug targets, combination therapies for study, and patient selection strategies in immuno-oncology.
“We’re all patients,” noted Dr. Michelle McMurry-Heath, a panelist in the first plenary session that kicked off ISPOR 2018, a 5-day conference devoted to health economics and outcomes research (HEOR) in Baltimore at the end of May. ...read more
This webinar replay reviews how the IBM Global Business Services (GBS) team generated actionable insights by applying machine learning on integrated EHRs (IBM Explorys clinical data set) and has thus helped life science companies tailor their business strategies and achieve research breakthroughs. ...read more
Watch the video Jupiter Medical Center in south Florida is the first U.S. regional medical center to adopt Watson for Oncology. See how Watson is providing insights to help Jupiter’s clinicians deliver evidence-based cancer care in the community setting. ...read more